David P Foley, MD


  • Folkert O. Belzer Chair, Division of Transplantation
  • Program Director, Abdominal Transplant Surgery Fellowship

(608) 263-2527

Clinical Science Center
600 Highland Avenue
Madison WI 53792


  • MD, Boston University, 1994
  • General Surgery Residency, University of Massachusetts Medical School, 1994-2001
  • Surgical Research Fellowship, University of Massachusetts Department of Surgery, 1996-1998
  • Transplant Surgical Fellow, University of Wisconsin Hospital and Clinics, Madison, WI, 2001-2003


Castle Connolly America’s Top Doctors Surgery

Madison Magazine Top Docs 2016 Award Surgery, Transplantation

Dr. Foley is involved with the following professional societies:

  • American Society of Transplant Surgeons
  • American Society of Transplantation
  • American Association for the Study of Liver Diseases
  • Association for Academic Surgery
  • Surgical Biology Club II
  • Society of University Surgeons
  • Central Surgical Association
  • Transplantation Society
  • Americas Hepato-Pancreato-Biliary Association
  • International Liver Transplant Society

Dr. Foley has been very active in leadership positions in national surgical and transplant societies. He has served as Co-Chair for the Grants Review Committee for the American Society of Transplant Surgeons. He served on the Executive Committee for the Association for Academic Surgery and Co-Chair of the Education Committee. He has been the Co-Chair and Chair of the Executive Committee for the Liver and Intestine Community of Practice for the American Society of Transplantation.

Clinical Specialties

Dr. Foley is certified by the American Board of Surgery in General Surgery. Dr. Foley’s clinical focus is in liver and kidney transplantation.

Research Interests

Dr. Foley’s clinical research interests include studying protective strategies to decrease organ damage and enhance organ function after kidney and liver transplantation. Dr. Foley focuses on identifying and modifying clinical risk factors that lead to poor liver function after liver transplantation. These include studying the use of older donor livers, livers recovered from donation after circulatory determination of death donors, and livers with steatosis. In addition, Dr. Foley leads clinical studies aimed at decreasing delayed kidney function after kidney transplantation.

Dr. Foley’s basic research efforts are focused on identifying novel protective strategies to minimize ischemia-reperfusion injury (IRI) in liver and kidney transplantation. More specifically, his laboratory investigates the cell-specific effects of augmenting endogenous antioxidant pathways in the setting of hepatic and renal IRI. Activation of these pathways in a cell-specific manner can decrease oxidative stress and may promote cellular recovery from these deleterious processes. The ultimate goal is to discover new pharmacologic therapies that can decrease IRI and improve organ function after kidney and liver transplantation.

Recent Publications

  • Strategies to Improve the Utilization and Function of DCD Livers.
    Kim SC, Foley DP
    Transplantation 2023 Jul 27;
    [PubMed ID: 37496117]

  • A Randomized Controlled Trial of Envarsus Versus Immediate Release Tacrolimus in Kidney Transplant Recipients With Delayed Graft Function.
    Parajuli S, Muth B, Bloom M, Ptak L, Aufhauser D, Thiessen C, Al-Adra D, Mezrich J, Neidlinger N, Odorico J, Wang JG, Foley D, Kaufman D, Mandelbrot DA
    Transplant Proc 2023 Sep; 55(7): 1568-1574
    [PubMed ID: 37394382]

  • Extracellular Vesicle-associated GARP/TGFβ:LAP Mediates "Infectious" Allo-tolerance.
    Burlingham WJ, Jankowska-Gan E, Fechner JH, Little CJ, Wang J, Hong S, Molla M, Sullivan JA, Foley DP
    Transplant Direct 2023 Jun; 9(6): e1475
    [PubMed ID: 37250483]

  • Psychosocial assessment in liver transplantation (LT): an analysis of short-term outcomes.
    Matthews LA, Musto JA, Deiss-Yehiely N, Daniel KE, Lightbourn C, Garvey M, Osman F, Foley DP, Rice JR, Lucey MR
    Hepatol Commun 2023 Jan 01; 7(1): e0017
    [PubMed ID: 36633478]

  • Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial.
    Hricik DE, Armstrong B, Alhamad T, Brennan DC, Bromberg JS, Bunnapradist S, Chandran S, Fairchild RL, Foley DP, Formica R, Gibson IW, Kesler K, Kim SJ, Mannon RB, Menon MC, Newell KA, Nickerson P, Odim J, Poggio ED, Sung R, Shapiro R, Tinckam K, Vincenti F, Heeger PS
    J Am Soc Nephrol 2023 Jan 01; 34(1): 145-159
    [PubMed ID: 36195441]

All Publications on PubMed